Company profile: Compass Pathways
1.1 - Company Overview
Company description
- Provider of psilocybin-based mental health therapies and research for treatment-resistant depression, PTSD, and anorexia nervosa. Offers COMP360 psilocybin treatment administered with psychological support, a therapist training programme, a Discovery Center for preclinical studies, and support for investigator-initiated studies, conducting clinical trials and research on psilocybin therapy.
Products and services
- COMP360 psilocybin treatment: Investigational psilocybin-based therapy for treatment-resistant depression, PTSD, and anorexia nervosa, administered with psychological support in controlled clinical research
- Therapist training programme: Standardized program that trains therapists to administer COMP360 psilocybin treatment, incorporating theoretical and practical skills training
- Investigator-initiated studies: Externally-led research studies supported by COMPASS Pathways that explore COMP360 psilocybin in various mental health conditions beyond company-sponsored trials
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Compass Pathways
SwanBio Therapeutics
HQ: United States
Website
- Description: Provider of gene therapy focused on genetically defined therapies for neurological disorders. Offerings include SBT101, a candidate for adrenomyeloneuropathy targeting ABCD1 via AAV9; pipeline development in spinal cord-related indications; clinical trials, including a Phase 1/2 study of SBT101 and natural history studies of AMN; and patient and family resources, including trial information and compassionate use policies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SwanBio Therapeutics company profile →
Marinus Pharmaceuticals
HQ: United States
Website
- Description: Provider of drugs and clinical research for seizure disorders. Offerings include ganaxolone, a GABAA receptor modulator for status epilepticus and rare epilepsies. The company reformulates, develops, and commercializes therapies and conducts clinical trials, and also targets neurological, psychiatric, and pain disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marinus Pharmaceuticals company profile →
Synaptive Medical
HQ: Canada
Website
- Description: Provider of neurosurgery, medical imaging and surgical navigation solutions, including the Synaptive Integrated Suite to integrate information and automation across interventions; Modus X robotic exoscope with 4K 3D and fluorescence visualization; Modus Plan automatic tractography segmentation; Modus Nav instrument tracking via intraoperative tractography; Synaptive MRI point-of-care MRI; ImageDrive zero-footprint HTML5 viewer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synaptive Medical company profile →
Cerus Endovascular
HQ: United Kingdom
Website
- Description: Provider of interventional neuroradiology devices and delivery systems, including the e-clipse aneurysm occlusive device that addresses neurovascular aneurysm procedures currently attempted by surgical clipping, minimally invasive metal coils, and liquid embolics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerus Endovascular company profile →
Longeviti Neuro Solutions
HQ: United States
Website
- Description: Provider of implantable neurosurgical devices, developing and commercializing these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Longeviti Neuro Solutions company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Compass Pathways
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Compass Pathways
2.2 - Growth funds investing in similar companies to Compass Pathways
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Compass Pathways
4.2 - Public trading comparable groups for Compass Pathways
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →